Barely Significant
← all excerpts

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).

Hum Reprod · 2024 · PMC11144970 · PMID 38648863

Europe PMCDOI
1
hedged sentence
0.2790
closest p · 5.6× alpha
0.2790
boldest claim

The sentences

showed a trendP = 0.279not close (p > 0.1)
Although the 75 mg dose showed a trend toward reduction in non-menstrual pelvic pain at 3 months relative to the placebo, it was not statistically significant ( P = 0.279).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.